Superficial and muscle-invasive bladder cancer: Principles of management for outcomes assessments

Dipen J. Parekh, Bernard H. Bochner, Guido Dalbagni

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Bladder cancer is a heterogeneous disease. Non-muscle-invasive bladder cancer embraces a spectrum of tumors with varying degrees of clinical behavior. Transurethral resection remains the surgical mainstay for the treatment of non-muscle-invasive bladder cancer. In an attempt to decrease the recurrence or progression rate, intravesical chemotherapy or immunotherapy is also used. Radical cystectomy with bilateral pelvic lymph node dissection remains the gold standard for treating muscle-invasive bladder cancer. Over the last decade, the orthotopic neobladder has gained widespread popularity as the preferred mode of urinary diversion in both males and females with similar oncologic and functional outcomes. Well-designed trials with effective chemotherapy have shown a beneficial role for neoadjuvant chemotherapy.

Original languageEnglish (US)
Pages (from-to)5519-5527
Number of pages9
JournalJournal of Clinical Oncology
Volume24
Issue number35
DOIs
StatePublished - Dec 10 2006
Externally publishedYes

Fingerprint

Urinary Bladder Neoplasms
Outcome Assessment (Health Care)
Muscles
Drug Therapy
Urinary Diversion
Cystectomy
Lymph Node Excision
Immunotherapy
Recurrence
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Superficial and muscle-invasive bladder cancer : Principles of management for outcomes assessments. / Parekh, Dipen J.; Bochner, Bernard H.; Dalbagni, Guido.

In: Journal of Clinical Oncology, Vol. 24, No. 35, 10.12.2006, p. 5519-5527.

Research output: Contribution to journalArticle

Parekh, Dipen J. ; Bochner, Bernard H. ; Dalbagni, Guido. / Superficial and muscle-invasive bladder cancer : Principles of management for outcomes assessments. In: Journal of Clinical Oncology. 2006 ; Vol. 24, No. 35. pp. 5519-5527.
@article{3387a50da77b440998720abe8b9c449d,
title = "Superficial and muscle-invasive bladder cancer: Principles of management for outcomes assessments",
abstract = "Bladder cancer is a heterogeneous disease. Non-muscle-invasive bladder cancer embraces a spectrum of tumors with varying degrees of clinical behavior. Transurethral resection remains the surgical mainstay for the treatment of non-muscle-invasive bladder cancer. In an attempt to decrease the recurrence or progression rate, intravesical chemotherapy or immunotherapy is also used. Radical cystectomy with bilateral pelvic lymph node dissection remains the gold standard for treating muscle-invasive bladder cancer. Over the last decade, the orthotopic neobladder has gained widespread popularity as the preferred mode of urinary diversion in both males and females with similar oncologic and functional outcomes. Well-designed trials with effective chemotherapy have shown a beneficial role for neoadjuvant chemotherapy.",
author = "Parekh, {Dipen J.} and Bochner, {Bernard H.} and Guido Dalbagni",
year = "2006",
month = "12",
day = "10",
doi = "10.1200/JCO.2006.08.5431",
language = "English (US)",
volume = "24",
pages = "5519--5527",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "35",

}

TY - JOUR

T1 - Superficial and muscle-invasive bladder cancer

T2 - Principles of management for outcomes assessments

AU - Parekh, Dipen J.

AU - Bochner, Bernard H.

AU - Dalbagni, Guido

PY - 2006/12/10

Y1 - 2006/12/10

N2 - Bladder cancer is a heterogeneous disease. Non-muscle-invasive bladder cancer embraces a spectrum of tumors with varying degrees of clinical behavior. Transurethral resection remains the surgical mainstay for the treatment of non-muscle-invasive bladder cancer. In an attempt to decrease the recurrence or progression rate, intravesical chemotherapy or immunotherapy is also used. Radical cystectomy with bilateral pelvic lymph node dissection remains the gold standard for treating muscle-invasive bladder cancer. Over the last decade, the orthotopic neobladder has gained widespread popularity as the preferred mode of urinary diversion in both males and females with similar oncologic and functional outcomes. Well-designed trials with effective chemotherapy have shown a beneficial role for neoadjuvant chemotherapy.

AB - Bladder cancer is a heterogeneous disease. Non-muscle-invasive bladder cancer embraces a spectrum of tumors with varying degrees of clinical behavior. Transurethral resection remains the surgical mainstay for the treatment of non-muscle-invasive bladder cancer. In an attempt to decrease the recurrence or progression rate, intravesical chemotherapy or immunotherapy is also used. Radical cystectomy with bilateral pelvic lymph node dissection remains the gold standard for treating muscle-invasive bladder cancer. Over the last decade, the orthotopic neobladder has gained widespread popularity as the preferred mode of urinary diversion in both males and females with similar oncologic and functional outcomes. Well-designed trials with effective chemotherapy have shown a beneficial role for neoadjuvant chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=34247346908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247346908&partnerID=8YFLogxK

U2 - 10.1200/JCO.2006.08.5431

DO - 10.1200/JCO.2006.08.5431

M3 - Article

C2 - 17158537

AN - SCOPUS:34247346908

VL - 24

SP - 5519

EP - 5527

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 35

ER -